PubMed=9973934; DOI=10.1016/S0165-4608(98)00122-8
Nelson M.A., Ariza M.E., Yang J.-M., Thompson F.H., Taetle R., Trent J.M., Wymer J., Massey-Brown K.S., Broome-Powell M., Easton J., Lahti J.M., Kidd V.J.
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Cancer Genet. Cytogenet. 108:91-99(1999)

PubMed=10952317; DOI=10.1038/35020115
Bittner M., Meltzer P.S., Chen Y.-D., Jiang Y., Seftor E.A., Hendrix M.J.C., Radmacher M.D., Simon R.M., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F.M., Gooden G.C., Lueders J., Glatfelter A., Pollock P.M., Carpten J.D., Gillanders E.M., Leja D., Dietrich K., Beaudry C., Berens M.E., Alberts D.S., Sondak V.K., Hayward N.K., Trent J.M.
Molecular classification of cutaneous malignant melanoma by gene expression profiling.
Nature 406:536-540(2000)

PubMed=12115485; DOI=10.1002/ijc.10422
Feng Y.-M., Shi J.-Q., Goldstein A.M., Tucker M.A., Nelson M.A.
Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families.
Int. J. Cancer 99:834-838(2002)

PubMed=24879157; DOI=10.4161/auto.28594; PMCID=PMC4091172
Goodall M.L., Wang T., Martin K.R., Kortus M.G., Kauffman A.L., Trent J.M., Gately S., MacKeigan J.P.
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
Autophagy 10:1120-1136(2014)